RM Magazine

RM logo

Drug development

Patients begin CAR-T cell treatment trial

The Royal Marsden has recently been approved by NHS England to deliver a new type of immunotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma.

Drug development

70 years of innovation at The Royal Marsden

As the NHS celebrates its 70th birthday in July 2018, we take a look back at what The Royal Marsden has achieved in the fields of drug development, radiotherapy and surgery during that time.

Jatinder Harchowal led the RM Partners biosimilars project

Drug development

Carbon copies

The Royal Marsden has led the drive to bring biosimilars – near-identical replicas of vital drugs that are just as effective as the originals, yet cost far less – to more cancer patients

Drug development

Celebrating a decade of pioneering drug development

Staff at the Oak Foundation Drug Development Unit (DDU) have celebrated a decade of innovation by showcasing the work of the unit to patients, relatives and hospital colleagues at a special evening event